"" "" News 2020

News 2020

Novo Nordisk UK prepared for Brexit outcomes

Gatwick, 14 September 2020

At Novo Nordisk our first commitment is to ensure that patients treated with our medicines are able to access them, regardless of the outcome of Brexit.

Throughout the COVID-19 pandemic we have worked successfully with Government, NHS England and charities to ensure that the supply of medicines has remained consistent with the needs of patients and the NHS. The UK has benefitted through this period from having heightened Novo Nordisk medicines stocks in the country due to Brexit preparation.

Read more....

 

Rybelsus®  (semaglutide tablets), the world’s first and only oral GLP-1 RA, now available in the UK to treat type 2 diabetes

Gatwick, UK, 01 September, 2020 – Novo Nordisk announced today the launch of Rybelsus® (semaglutide tablets) in the UK, the world’s first and only oral GLP-1 RA and first ‘protein in a pill’ treatment for T2D. Oral semaglutide is now available for physicians in the UK, including GPs, to prescribe for adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control.

Read more.....

 

Novo Nordisk UK collaborates in a unique partnership with NHS and Diabetes UK to support people living with diabetes during COVID-19 via Helpline

Gatwick, May 20, 2020 – As the biggest insulin supplier in the UK with over 95 years of innovation in diabetes care, Novo Nordisk is dedicated to supporting people with diabetes during the current Coronavirus outbreak.

Today, the NHS has expanded it’s offer to help people with diabetes by providing a new dedicated helpline. The helpline will support people living with diabetes and their families during the COVID-19 outbreak. The initiative came from discussions and collaboration between NHS England, DUK and Novo Nordisk, including Novo Nordisk Diabetes Specialist Nurses who are volunteering on this helpline.

Read more.....

 


Novo Nordisk UK confident of supply amid Coronavirus outbreak

Gatwick, April 20, 2020 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is dedicated to ensuring medicine supplies are unaffected during the current Coronavirus outbreak. Our patients, the NHS and our people are at the heart of everything we do.

We understand the pressure on the NHS at this time, and to minimise the possibility of infection moving from one service to another, we have invested in technology to allow our teams to work from home virtually.

 

Read more.....

 

Novo Nordisk UK confident of Hormone Replacement Therapy (HRT) supply amid Coronavirus outbreak

Gatwick, March 24, 2020 – Novo Nordisk is dedicated to ensuring medicine supplies are unaffected during the current Coronavirus outbreak. Our patients, the NHS and our people are at the heart of everything we do.

We are aware of the ongoing HRT shortages being experienced by some pharmaceutical companies, and how distressing this must be for those women affected.

Novo Nordisk stocks are not affected by these current supply issues and, as always, our priority is ensuring that people receive the care and treatment that they need.
 

Read more.....

 

Novo Nordisk UK confident of supply amid Coronavirus outbreak

Gatwick, March 19, 2020 – As the biggest insulin supplier in the UK and with 95 years of innovation in diabetes care, Novo Nordisk is dedicated to ensuring medicine supplies are unaffected during the current Coronavirus outbreak. Our patients, the NHS and our people are at the heart of everything we do.
 

Read more.....

 

 

This page is intended for UK consumer media, UK trade/medical media and members of the UK public.


VEEVA#: UK20RYB00114